Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus KANAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus KANAMYCIN SULFATE.
GENTAFAIR vs KANAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic